Table II.

Effect of puerarin combined with 5-FU or alone on hepatic and renal function.

Group	n	ALT (U/l)	AST (U/l)	Urea (μmol/l)	Cr (μmol/l)
Puerarin	6	34.33±4.72	131.50±12.88	7.25±2.50	17.69±2.48
5-FU	6	33.67±3.44	129.17±26.63	6.96±1.29	15.72±1.29
Puerarin+5-FU	6	35.50±10.37	136.33±17.50	7.34±0.53	19.21±5.59
Tumor control	6	31.67±10.56	124.50±22.49	7.01±0.44	15.81±2.91
Normal control	6	32.17±8.70	130.17±15.08	7.04±0.81	16.62±2.48

Values are presented as the mean ± standard deviation (SD), with n=6 mice/group. Groups were treated as follows: Puerarin (30 mg/kg/day), 5-FU (12 mg/kg/day), puerarin (30 mg/kg/day)+5-FU (12 mg/kg/day), tumor control (saline of equal volume) or normal control (no injection). No differences were observed in serum ALT, AST, urea or Cr among the groups (P>0.05). ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, serum creatinine; 5-FU, 5-fluorouracil.